-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Indinavir sulfate
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/157810-81-6.gif)
| Category | HIV Protease |
| CAS | 157810-81-6 |
| Description | Indinavir is a protease inhibitor used as a component of highly active antiretroviral therapy to treat HIV infection and AIDS. It inhibits the HIV-1 protease with an IC50 value of 0.41 nM and Ki value of 0.24 nM. However, indinavir demonstrates up to a 50-fold loss in potency against the HIV-1 protease drug-resistant mutations PRL24I, PRI50V, and PRG73S (Kis = 1.4, 27, and 0.55 nM). |
Product Information
| Synonyms | Crixivan sulfate; MK-639 sulfate; L-735524 sulfate; MK639 sulfate; L735524 sulfate; MK 639 sulfate; L 735524 sulfate |
| IUPAC Name | (2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-[[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino]-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide;sulfuric acid |
| Molecular Weight | 711.87 |
| Molecular Formula | C36H49N5O8S |
| Canonical SMILES | CC(C)(C)NC(=O)C1CN(CCN1CC(CC(CC2=CC=CC=C2)C(=O)NC3C(CC4=CC=CC=C34)O)O)CC5=CN=CC=C5.OS(=O)(=O)O |
| InChI | InChI=1S/C36H47N5O4.H2O4S/c1-36(2,3)39-35(45)31-24-40(22-26-12-9-15-37-21-26)16-17-41(31)23-29(42)19-28(18-25-10-5-4-6-11-25)34(44)38-33-30-14-8-7-13-27(30)20-32(33)43;1-5(2,3)4/h4-15,21,28-29,31-33,42-43H,16-20,22-24H2,1-3H3,(H,38,44)(H,39,45);(H2,1,2,3,4)/t28-,29+,31+,32-,33+;/m1./s1 |
| InChIKey | NUBQKPWHXMGDLP-BDEHJDMKSA-N |
| Boiling Point | 877.9°C at 760 mmHg |
| Melting Point | 150-153°C |
| Flash Point | 484.7°C |
| Purity | >98% |
| Solubility | In Vitro: DMSO : ≥ 100 mg/mL (140.48 mM) H2O : 50 mg/mL (70.24 mM; Need ultrasonic) |
| Appearance | White to off-white (Solid) |
| Application | Hiv protease inhibitors. |
| Storage | -20°C, sealed storage, away from moisture * In solvent : -80°C 6 months; -20°C 1 month (sealed storage, away from moisture) |
| Complexity | 1030 |
| Exact Mass | 711.33018471 |
| In Vitro | Indinavir sulfate (0-50 µM; 18 h) blocks lymphocyte cell cycle in G0/G1 phase in PBMCs cells and impairs lymphoproliferative responses. Indinavir sulfate (40 µM-40 nM; 5 days) inhibits cell invasion and (40 µM-40 nM; 48 h) MMPs-2 activation of the Huh7 and SK-HEP-1 hepatocarcinoma cells in vitro. |
| In Vivo | Indinavir sulfate (70 mg/kg; i.g.; once a day for 3 weeks) inhibits the growth of hepatocarcinoma cells in vivo. |
| PSA | 201.01000 |
| Target | HIV; HIV Protease; SARS-CoV; Apoptosis; MMP |
| Vapor Pressure | 5.56E-33mmHg at 25°C |
